Wilate - Von Willebrand Factor/coagulation Factor Viii Complex (human) Powder, For Solution
Product Images NDC 68982-182

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Wilate - Von Willebrand Factor/coagulation Factor Viii Complex (human) (NDC 68982-182). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Octapharma Usa Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image File (Img0001)

This text provides a formula for calculating the required IU (international units) of a medication based on body weight and desired VWFRCo (von Willebrand Factor Ristocetin Cofactor) rise, as well as the expected VWE-RCo (von Willebrand Factor Ristocetin Cofactor activity) rise. The equation also includes conversion factors between IU, body weight per IU/dL, and expected rise percentage.*

FDA Label Image

Image File (Img0002)

FDA Label Image

Image File (Img0003)

The text describes a formula for calculating the required IU of Factor VIIT rise based on body weight (in kg) and desired percentage increase, as well as the expected percentage rise in Factor VIIT levels based on the administered IU and body weight.*

FDA Label Image

Image File (Img0004)

FDA Label Image

Image File (Img0005)

FDA Label Image

Image File (Img0006)

FDA Label Image

Image File (Img0007)

FDA Label Image

Image File (Img0008)

This text provides information on the Virus Reduction Factor for enveloped and non-enveloped viruses, along with the production steps that were applied to test viruses including HIV-1, SBV, BVDV, REO3, HAV, and PPV. The text also mentions different treatments with their respective percentage reduction values for viruses. The Global Reduction Factor values are also given for the utilized treatments.*

FDA Label Image

Image File (Img0009)

This appears to be a table showing data related to initial and subsequent doses of subjects across different locations. The first column is for all subjects with a total count of 45 while the second column is restricted to subjects aged between 5 to 16 years, with a count of 11. The subsequent columns show the location/type of infusion, the number of doses administered, the average dose size (mean) plus the standard deviation (SD), and the range of infusions. The last row shows data related to the Otice location, specifying the count of subjects, average dose size, and range of infusions.*

FDA Label Image

Image File (Img0010)

FDA Label Image

Image File (Img0011)

FDA Label Image

Image File (Img0012)

FDA Label Image

Image File (Img0013)

FDA Label Image

Image File (Img0014)

Product Name: wilate® Purpose: Used for Intravenous injection only Ingredients: von Willebrand Factor/Coagulation Factor VIII Complex (Human), Solvent Detergent and Heat Treated Dosage: 500 IU Preparation: Powder for intravenous injection upon reconstitution with supplied diluent Note: The additional text is not-readable and non-English characters.*

FDA Label Image

Img0015

Description: von Willebrand Factor and Coagulation Factor VII Complex (Human) are combined in a medication called Wilate, which is available in a powder form for intravenous injection. This medication is for prescription use only and should only be administered after being reconstituted with the provided diluent. It has a total protein content of up to 15.0 and is treated with solvent detergent and heat.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.